Alexion (ALXN, $97.83) to buy Portola for $1.41 billion.

Alexion Pharmaceuticals  has agreed to buy Portola Pharmaceuticals   for $1.41 billion. 

The deal,  where Alexion will pay $18 a share for the acquisition,  is expected to help Alexion boost its portfolio by including Portola's coagulation factor Xa drug Andexxa. "The acquisition of Portola represents an important next step in our strategy to diversify beyond C5," Alexion Chief Executive Ludwig Hantson said in a statement.

The acquisition is expected to in the third quarter. However, it is subject to approval by holders of a majority of Portola shares outstanding and by regulators.

Contributor

Sergey Savastiouk|Expert

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.